European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- (Full Version)

For a pharmaceutical manufacturer, is more than a technical document. It is the legal gateway to sell tablets in Europe. If your QC report claims "Conforms to Ph. Eur. 0478," you are legally declaring that every batch released meets the standards for:

However, the monograph reveals a clever "regulatory escape hatch." It acknowledges that for some drugs (like insoluble antacids or simple water-soluble vitamins), dissolution testing is unnecessary. It allows manufacturers to prove that the simpler disintegration test is sufficient—a perfect example of risk-based regulation. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more ICH Q4B Annex 5 - Disintegration Test General Chapter - EMA For a pharmaceutical manufacturer, is more than a

This is arguably the most critical safety and efficacy test. It ensures that each tablet in a batch contains the active substance within a narrow range (typically 85–115% of the label claim). The test is performed according to General Chapter 2.9.40, using either content uniformity (individual assay of 10 tablets) or mass variation (weighing tablets for potent drugs). Failure here indicates poor manufacturing mixing or compression, leading to underdosing (ineffectiveness) or overdosing (toxicity). This is for informational purposes only

The monograph distinguishes between several categories of tablets, each with its own specific requirements:

: Intended to be dissolved or dispersed in water prior to use.